- Home
- WNS vs VKTX Comparison
WNS vs VKTX Comparison
Compare WNS & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNS
- VKTX
- Stock Information
- Founded
- WNS 1996
- VKTX 2012
- Country
- WNS India
- VKTX United States
- Employees
- WNS N/A
- VKTX N/A
- Industry
- WNS Business Services
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- WNS Consumer Discretionary
- VKTX Health Care
- Exchange
- WNS Nasdaq
- VKTX Nasdaq
- Market Cap
- WNS 2.8B
- VKTX 2.8B
- IPO Year
- WNS N/A
- VKTX 2015
- Fundamental
- Price
- WNS $58.33
- VKTX $27.14
- Analyst Decision
- WNS Buy
- VKTX Buy
- Analyst Count
- WNS 8
- VKTX 12
- Target Price
- WNS $63.00
- VKTX $84.00
- AVG Volume (30 Days)
- WNS 736.4K
- VKTX 2.9M
- Earning Date
- WNS 07-17-2025
- VKTX 07-23-2025
- Dividend Yield
- WNS N/A
- VKTX N/A
- EPS Growth
- WNS 24.08
- VKTX N/A
- EPS
- WNS 3.71
- VKTX N/A
- Revenue
- WNS $1,314,942,000.00
- VKTX N/A
- Revenue This Year
- WNS $5.56
- VKTX N/A
- Revenue Next Year
- WNS $9.37
- VKTX N/A
- P/E Ratio
- WNS $15.63
- VKTX N/A
- Revenue Growth
- WNS N/A
- VKTX N/A
- 52 Week Low
- WNS $42.62
- VKTX $18.92
- 52 Week High
- WNS $72.11
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- WNS 47.09
- VKTX 48.69
- Support Level
- WNS $56.30
- VKTX $26.66
- Resistance Level
- WNS $57.90
- VKTX $28.33
- Average True Range (ATR)
- WNS 2.14
- VKTX 1.34
- MACD
- WNS 0.39
- VKTX -0.12
- Stochastic Oscillator
- WNS 84.45
- VKTX 32.21
About WNS WNS (Holdings) Limited Sponsored ADR (Jersey)
WNS (Holdings) Ltd is a Global provider of business process management (BPM) services, offering comprehensive data, voice, analytical, and business transformation services with a blended onshore, nearshore and offshore delivery model. The company's segment includes Banking/Financial Services, and Insurance; Travel, Shipping/Logistics, and Utilities; Manufacturing/Retail/Consumer, Hi-tech/Professional Services, and Procurement; Healthcare/Life Sciences. Geographically the company generates the majority of its revenue from North America (primarily the US), followed by the UK. The company also has a presence in Australia, Europe (excluding the UK), and South Africa.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.